1Berg PA, Klein R. Anti-mitochondrial antibodies in primary biliary cirrhosis and other disorders: definition and clinical relevance. Dig Dis 1992; 10:85-101.
2Bunn CC, McMorrow M. Anti-M4 antibodies measured by a sulphite oxidase ELISA in patients with both anti-centromere and anti-M2 antibodies. Clin Exp Immunol 1995;102:131-136.
3Joshi S, Cauch-Dudek K, Heathcote EJ, Lindor K, Jorgensen R, Klein R. Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis? Am J Gastroenterol 2002; 97:999-1002.
4Heathcote EJ. Management of Primary Biliary Cirrhosis.Hepatology 2000; 31:1005-1013.
5Dickson ER, Grambsch PM, Fleming TR, Fisher LD,Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10:1-7.
6Sakugawa H, Nakasone H, Nakayoshi T, Yamashiro T,Maeshiro T, Kobashigawa K, Kinjo F, Saito A, Zukeran H,Nakanuma Y, Ohba K. Epidemiology of primary biliary cirrhosis among women with elevated gamma-glutamyl transpeptidase levels in Okinawa, Japan. Hepatol Res 2003;26:330-336.
7Flisiak R, Wiercinska-Drapalo A, Prokopowicz D. Antibodies against M2 antigen in differential diagnosis of primary biliary cirrhosis. Pol Merk Lek 2000; 8:373-375.
8Reisman Y, van Dam GM, Gips CH, Lavelle SM, Euricterus PM. Survival probabilities of Pugh-Child-PBC classified patients in the euricterus primary biliary cirrhosis population,based on the Mayo clinic prognostic model. Euricterus Project Management Group. Hepatogastroenterology 1997; 44: 982-989.
9Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis:follow-up for up to 28 years. Gastroenterology 2002; 123:1044-1051.
10Krzeski P, Zych W, Kraszewska E, Milewski B, Butruk E,Habior A. Is serum bilirubin concentration the only valid prognostic marker in primary biliary cirrhosis? Hepatology 1999;30:865-869.
2Graham KL, Robinson WH, Steinman L, et al. High-throughput methods for measuring autoantibodies in systemic lupus ezythematosus and other autoimmune diseases. Autoimmunity, 2004,37:269-272.
3Lyons R, Narain S, Nichols C, et al. Effective use of autoantibody tests in the diagnosis of systemic autoimmune disease. Ann N Y Acad Sci, 2005,1050:217-228.
4Ghirardello A, Doria A, Zampieri S, et al. Antinueleosome antibodies in SLE: a two year follow-up study of 101 patients. J Autoimmun, 2004,22:235-240.
5Rumore PM, Steinman CR. Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as muhimedia complex bound to histone. J Clin Invest, 1990,86:69.
6Villalta D, Tozzoli R, Bizzaro N, et al. The relevance of autoantigen source and cutoff definition in antichromatin (nucleosome) antibody immunoassays. Ann N Y Acad Sci, 2005,1050 : 176-184.
7van Gaalen FA, Visser H, Huizinga TW. A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis, 2005,64:1510-2.
8Collin P, Kaukinen K, Vogelsang H, et al. Antiendomysial and antihuman recombinant tissue transglutaminase antibodies in the diagnosis of celiac disease : a biopsy-proven european multicentre study. Eur J Gastroenterol Hepatol, 2005,17:85-91.
9Costagliola S, Morgenthaler NG, Hoermann R, et al. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. J Clin Endoerinol Metab, 1999,84:90-97.
10Schellekens GA, Visser H, de-Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic eitrullinated peptide. Arthritis Rheum, 2000,43 : 155-163.
